From Medscape Allergy & Immunology

Coverage from the

American College of Allergy, Asthma, and Immunology (ACAAI) 2022 Annual Meeting

November 10 - 14, 2022; Louisville, Kentucky

November 10 - 14, 2022 Louisville, Kentucky

ACAAI 2022 Peanut-Allergic Toddlers Also Benefit From Oral Immunotherapy With Palforzia New research findings show that an FDA-approved oral immunotherapy for older children and adolescents safely increased peanut protein tolerance in peanut-allergic children aged 1-3 years.
Medscape Medical News, November 14, 2022
ACAAI 2022 Infant Anaphylaxis: Study Characterizes Symptoms, Treatment A study of infants who presented to the emergency department with anaphylaxis may better inform treatment in these patients.
Medscape Medical News, November 14, 2022

Conference News

ACAAI 2022 Chronic Spontaneous Urticaria: Up-Dosing MAB Helps Poor Response
Medscape Medical News, November 15, 2022
ACAAI 2022 Epicutaneous Immunotherapy Helps Young Peanut-Allergic Children
Medscape Medical News, November 15, 2022
ACAAI 2022 Peanut-Allergic Toddlers Also Benefit From Oral Immunotherapy With Palforzia
Medscape Medical News, November 14, 2022

ACAAI 2022 Infant Anaphylaxis: Study Characterizes Symptoms, Treatment
Medscape Medical News, November 14, 2022
ACAAI 2022 Epinephrine Autoinjectors Not Prescribed to All Who Need Them
Medscape Medical News, November 11, 2022

Disclaimer

Credit:
Lead image: Thomaskelley/Dreamstime

Medscape Allergy & Immunology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.